A cathinone is a beta-keto amphetamine, a stimulant phenethylamine bearing a ketone at the beta-carbon of the side chain. The class spans the natural alkaloid of the khat plant (Catha edulis) and the synthetic analogs derived from it.[1] Membership is defined by this single chemical feature, which alters pharmacokinetics and metabolism relative to the parent amphetamine series without changing the underlying monoaminergic mechanism.
Members span four structural modification axes — aromatic ring substitution, alpha-carbon side chain, nitrogen substituent, and methylenedioxy bridging — and group into three pharmacological subgroups. Prototypical members include methcathinone and the ring-substituted mephedrone, the methylenedioxy analogs methylone and ethylone, and the pyrrolidine derivatives MDPV and α-PVP. They differ in selectivity but converge on elevated synaptic monoamines.
Cathinones produce stimulant effects — increased energy, wakefulness, appetite suppression, and euphoria — with empathogenic warmth in members that recruit serotonin alongside dopamine and norepinephrine.[1] Natural cathinone has a long history of chewed-leaf use as a social stimulant in the Horn of Africa and Arabian Peninsula. The synthetic analogs entered recreational markets in the 2000s, often as substitutes for amphetamine or MDMA, and at higher exposures shade into agitation and sympathetic overload.
Pharmacology
All cathinones reach their psychoactive endpoint at the three monoamine plasma-membrane transporters — the dopamine transporter (DAT), the norepinephrine transporter (NET), and the serotonin transporter (SERT) — and their profile is set by the relative potency and mode of action at each.[1] The shared endpoint is elevated synaptic dopamine, norepinephrine, and (in some members) serotonin; the route to that endpoint varies across the class.
| Mechanism | Representative members | How it reaches the shared endpoint |
|---|---|---|
| Substrate releasing agent (DAT/NET-preferring) | methcathinone, 3-MMC, 2-MMC, clephedrone | Carrier-mediated efflux of dopamine and norepinephrine, with weaker serotonin component; profile sits near amphetamine |
| Non-selective releasing agent (DAT/NET/SERT) | mephedrone, methylone, ethylone, butylone, ephylone | Carrier-mediated efflux across all three monoamines, blending amphetamine- and MDMA-like profiles |
| Pyrrolidine-type reuptake blocker | MDPV, α-PVP, α-PHP, α-PiHP | Competitive blockade of DAT and NET without inducing efflux; high DAT selectivity |
Two modes of transporter interaction account for nearly all members. Substrate-type cathinones enter the terminal via the transporter and trigger non-exocytotic monoamine efflux, mirroring amphetamine; non-selective releasers add serotonin to the profile and behave more like MDMA.[1]
The pyrrolidine subgroup acts only as transporter blockers — they prevent reuptake but do not drive efflux, and their DAT selectivity is reported to be substantially higher than cocaine's, which correlates with stronger reinforcing efficacy in preclinical models.[2][3]
Natural cathinone is also distinguished from amphetamine by its metabolism: the beta-keto group is rapidly reduced to less potent metabolites (cathine and norephedrine), giving cathinone a shorter elimination half-life than its own metabolites after khat chewing.[4] For class-wide safety logic, mechanism detail matters less than the shared endpoint. Every member elevates catecholamines; the cardiovascular strain, hyperthermic risk, and reinforcing pull are common to all, and additive when members stack with each other or with other stimulants.
Substances
The brief's 22 members span the structural breadth of the class. The table picks representatives across the three pharmacological subgroups, not an exhaustive roster.
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| Methcathinone | Simple N-alkyl releaser | The parent N-methyl cathinone; closest in profile to amphetamine |
| ETH-CAT | Simple N-alkyl releaser | N-ethyl variant of methcathinone; lower-potency amphetamine-like profile |
| Mephedrone (4-MMC) | Ring-substituted non-selective releaser | 4-methyl substituted; historically the most widely encountered synthetic cathinone in Europe |
| 3-MMC, 2-MMC | Ring-substituted releaser | Positional isomers of mephedrone; appeared as substitutes after mephedrone scheduling |
| 3-CMC, clephedrone | Ring-halogenated releaser | Chloro-substituted analogs with amphetamine-leaning releasing profile |
| Mexedrone | Ring-substituted releaser | Methoxy analog of mephedrone; generally milder and lower-potency |
| Methylone, ethylone, butylone, ephylone | Methylenedioxy releaser | Beta-keto analogs of the MDxx series; serotonin-recruiting empathogen profile |
| MDPV | Pyrrolidine blocker | Pure DAT/NET blocker; strongly reinforcing in preclinical models |
| α-PVP, α-PHP, α-PiHP | Pyrrolidine blocker | Pyrovalerone-derived blockers; high DAT selectivity and short duration |
| Pentedrone, hexedrone, N-ethylhexedrone, NEP | Alpha-extended N-alkyl blocker | Non-pyrrolidine blockers across the intermediate-potency stimulant space |
| βk-2C-B | Hybrid cathinone–phenethylamine | Combines the cathinone scaffold with a 2C-B aromatic substitution; less characterised within the class |
These members differ in potency and selectivity, but every one elevates synaptic monoamines and carries the class-wide cardiovascular and reinforcing risk profile.
Subjective Effects
Across the class the subjective trajectory tracks a single axis — escalating monoamine excess — as exposure rises. Empathogenic colour is added where a member recruits serotonin alongside dopamine and norepinephrine.
| Exposure | Characteristic effects |
|---|---|
| Low | Increased energy, wakefulness, mood elevation, appetite suppression, talkativeness, mild empathogenic warmth in serotonin-recruiting members, and visible sympathetic stimulation (raised heart rate, dilated pupils, dry mouth) |
| Moderate–high | Intense euphoria, strong urge to redose, bruxism (jaw clenching), diaphoresis, anxiety, restlessness, and (in some users) mild perceptual disturbances |
| High | Severe agitation, paranoia, psychotic features, hyperthermia, and the sympathomimetic toxidrome of cardiovascular and thermal overload |
The same monoaminergic axis drives both the sought effects and the dangerous ones, and the short peak duration characteristic of most cathinones invites a compulsive redosing pattern that accelerates the move from one to the other.[2] Once the effect window closes, users commonly enter a "crash" phase — fatigue, depression, irritability, and difficulty concentrating — consistent with monoamine depletion across the class.[2]
Safety
Risk profile
The defining acute danger of the cathinone class is sympathomimetic and thermoregulatory overload — tachycardia, hypertension, hyperthermia, agitated psychosis, and rhabdomyolysis driven by sustained catecholamine excess. Severe presentations can progress to cardiac arrhythmia, seizures, acute kidney injury, and multiorgan failure.
Cardiovascular strain is the most consistent acute presentation. Tachycardia, hypertension, and palpitations dominate emergency-department case series across the class, and the pyrrolidine subgroup produces particularly intense cardiovascular effects in proportion to its high DAT and NET potency.[5][2]
Hyperthermia is a class-wide life-threatening complication, arising from monoaminergic thermoregulatory disruption and from sustained hyperkinetic muscle activity in agitated or seizing patients. Severe hyperthermia drives rhabdomyolysis, which in turn precipitates acute kidney injury and, in the worst cases, multiorgan failure.[6][7]
Acute psychosis — paranoia, aggressive behaviour, and hallucinations — is documented across all three pharmacological subgroups.[8] The excited delirium syndrome (extreme agitation, hyperthermia, unexpected strength) has been associated particularly with MDPV and α-PVP, and clinical management leans on benzodiazepines plus aggressive temperature control rather than antipsychotics alone.[6]
Suicidal ideation during and after intoxication is documented, with one study region reporting that roughly one-third of suicides in a single year involved active or recent synthetic cathinone users.[9]
Polydrug presentation is the norm rather than the exception. Surveillance data from US emergency departments found that just over half of bath-salts visits involved a concurrent substance.[10] Stacking with other stimulants (amphetamines, cocaine) compounds cardiovascular and hyperthermic strain. Stacking with depressants can mask the subjective intensity while the cardiovascular load continues — a particularly deceptive pattern.
Tolerance & dependence
Tolerance develops with regular use across the class, driven by downregulation of monoamine transporters and postsynaptic receptor desensitisation.[1] Cross-tolerance within the class is expected given the shared mechanism, and preclinical cross-tolerance to methamphetamine and cocaine has also been reported.
Dependence liability is high. Pyrrolidine cathinones — MDPV and α-PVP in particular — show reinforcing efficacy in preclinical self-administration paradigms that meets or exceeds methamphetamine.[3] The short peak duration of most members drives binge patterns: extended runs of repeated dosing that amplify both dependence formation and acute toxicity risk.[2] Survey work on heavy mephedrone users found that a substantial fraction met multiple criteria for stimulant use disorder.[5]
Withdrawal after sustained heavy use is not life-threatening in the way alcohol or benzodiazepine withdrawal can be — there is no class-wide seizure or delirium risk on cessation. The picture is instead one of neuropsychiatric rebound: depression, anhedonia, fatigue, irritability, hypersomnia, cravings, and difficulty concentrating, mirroring the stimulant withdrawal pattern seen with amphetamine and cocaine.[2] The depressive and anhedonic features can persist for weeks in heavy users, reflecting the time the monoamine systems take to recover.
Recovery
Cathinone dependence is treatable. There is no class-specific pharmacotherapy, so clinical management is supportive — addressing sleep, mood, hydration, and craving while the monoamine systems recover, with structured counselling for the binge pattern that drives most of the harm. If you or someone you know is using cathinones in a way that has become hard to stop, a clinician or a stimulant-focused treatment service can structure a stepwise recovery plan.
Recovery resources, crisis lines, and support pathways → View all
Sub-classes
Members
references
- [1]
- [2]
- [3] ^abDe Felice, L.J. and Glennon, R.A. and Negus, S.S. (2014) Synthetic cathinones: chemical phylogeny, physiology, and neuropharmacology — Life Sciences doi:10.1016/j.lfs.2013.10.029
- [4] ^Toennes, S.W. and Harder, S. and Schramm, M. and Niess, C. and Kauert, G.F. (2003) Pharmacokinetics of cathinone, cathine and norephedrine after the chewing of khat leaves — British Journal of Clinical Pharmacology doi:10.1046/j.1365-2125.2003.01834.x
- [5] ^abWeinstein A, Rosca P, Fattore L, London ED (2017) Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health — Frontiers in Psychiatry doi:10.3389/fpsyt.2017.00156
- [6] ^abBanks ML, Worst TJ, Rusyniak DE, Sprague JE (2014) Synthetic cathinones (bath salts) — Journal of Emergency Medicine doi:10.1016/j.jemermed.2013.11.104